Liisi Laaniste

Chief Scientific Offier CoSyne Therapeutics

Liisi holds a PhD from Imperial College London in Computational Systems Biology, focusing on the transformation of low-grade gliomas to high-grade tumours and identifying genetic vulnerabilities in glioblastoma. At Karolinska Institute, she studied neuroscience, concentrating on the epigenetics of neural stemness. During her medical science studies at Uppsala University, where she ranked first in her class, she researched brain tumour microenvironments and vasculature. Liisi graduated cum laude from the University of Tartu, conducting research in human genetics and metabolomics. Liisi has been awarded multiple scholarships, including the highly competitive Imperial College President’s scholarship. Liisi is driven by the intricate complexity of biology and is passionate about leveraging systems biology to bridge preclinical discoveries and patient benefit.

Seminars

Wednesday 18th February 2026
High-throughput Drug Perturbation in Patient-Derived Gliomaspheres Enables Patient Stratification
2:00 pm
  • Value of deep genetic characterisation and functional genomics on low-passage patient-derived glioma tumorspheres
  • Genetic biomarker identification and validation
  • Rapid clinical impact of tumour precision targeting by clinical stage drugs
Wednesday 18th February 2026
Driving the Use of Biomarker-Based Enrollment in GBM trials to Accelerate Clinical Success & Improve Patient Outcomes
1:30 pm
  • Addressing the lack of analysis of molecular data in current enrolment protocols for GBM trials
  • Discussing strategies to incorporate biomarker-based enrolment given the rise of personalized therapies
  • Establishing the efficacy of targeted treatments in recurrent GBM to accelerate the delivery of peronalized therapies
Liisi Laaniste, speaking at the 7th Glioblastoma Drug Development Summit